Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Krieger CC, Boutin A, Jang D, Morgan SJ, Banga JP, Kahaly GJ, Klubo-Gwiezdzinska J, Neumann S, Gershengorn MC.

Endocrinology. 2019 Jun 1;160(6):1468-1479. doi: 10.1210/en.2019-00055.

2.

Letter to the Editor: "Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy".

Neumann S, Krieger CC, Gershengorn MC.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1075-1076. doi: 10.1210/jc.2018-02103. No abstract available.

PMID:
30561709
3.

Thyroid Stimulating Hormone (TSH)/Insulin-like Growth Factor 1 (IGF1) Receptor Cross-talk in Human Cells.

Krieger CC, Morgan SJ, Neumann S, Gershengorn MC.

Curr Opin Endocr Metab Res. 2018 Oct;2:29-33. doi: 10.1016/j.coemr.2018.01.007. Epub 2018 Feb 5.

PMID:
30547142
4.

Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.

Dougherty JP, Springer DA, Cullen MJ, Gershengorn MC.

Behav Brain Res. 2019 Mar 15;360:255-261. doi: 10.1016/j.bbr.2018.12.011. Epub 2018 Dec 7.

PMID:
30529403
5.

Normal Human Thyrocytes in Culture.

Morgan SJ, Neumann S, Gershengorn MC.

Methods Mol Biol. 2018;1817:1-7. doi: 10.1007/978-1-4939-8600-2_1.

6.

Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.

Marcus-Samuels B, Krieger CC, Boutin A, Kahaly GJ, Neumann S, Gershengorn MC.

Thyroid. 2018 May;28(5):650-655. doi: 10.1089/thy.2018.0089. Epub 2018 Apr 30.

7.

Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro.

Neumann S, Eliseeva E, Boutin A, Barnaeva E, Ferrer M, Southall N, Kim D, Hu X, Morgan SJ, Marugan JJ, Gershengorn MC.

J Pharmacol Exp Ther. 2018 Jan;364(1):38-45. doi: 10.1124/jpet.117.244095. Epub 2017 Oct 31.

8.

T3 and Glucose Coordinately Stimulate ChREBP-Mediated Ucp1 Expression in Brown Adipocytes From Male Mice.

Katz LS, Xu S, Ge K, Scott DK, Gershengorn MC.

Endocrinology. 2018 Jan 1;159(1):557-569. doi: 10.1210/en.2017-00579.

9.

TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.

Krieger CC, Perry JD, Morgan SJ, Kahaly GJ, Gershengorn MC.

Endocrinology. 2017 Oct 1;158(10):3676-3683. doi: 10.1210/en.2017-00528.

10.

Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).

Neumann S, Gershengorn MC.

Thyroid. 2017 Nov;27(11):1459-1460. doi: 10.1089/thy.2017.0472. Epub 2017 Oct 17. No abstract available.

11.

De novo triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone.

Citterio CE, Veluswamy B, Morgan SJ, Galton VA, Banga JP, Atkins S, Morishita Y, Neumann S, Latif R, Gershengorn MC, Smith TJ, Arvan P.

J Biol Chem. 2017 Sep 15;292(37):15434-15444. doi: 10.1074/jbc.M117.784447. Epub 2017 Jul 25.

12.

Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.

Dougherty JP, Wolff BS, Cullen MJ, Saligan LN, Gershengorn MC.

Pharmacol Res. 2017 Oct;124:1-8. doi: 10.1016/j.phrs.2017.07.012. Epub 2017 Jul 15.

13.

TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Krieger CC, Neumann S, Marcus-Samuels B, Gershengorn MC.

Thyroid. 2017 May;27(5):746-747. doi: 10.1089/thy.2017.0105. Epub 2017 Mar 27. No abstract available.

14.

Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture.

Morgan SJ, Neumann S, Marcus-Samuels B, Gershengorn MC.

Front Endocrinol (Lausanne). 2016 Dec 26;7:168. doi: 10.3389/fendo.2016.00168. eCollection 2016.

15.

Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.

Place RF, Krieger CC, Neumann S, Gershengorn MC.

Br J Pharmacol. 2017 Feb;174(4):328-340. doi: 10.1111/bph.13693. Epub 2017 Jan 27.

16.

Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.

Morgan SJ, Neumann S, Marcus-Samuels B, Gershengorn MC.

Thyroid. 2016 Dec;26(12):1794-1803. Epub 2016 Oct 18.

17.

An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties.

Neumann S, Padia U, Cullen MJ, Eliseeva E, Nir EA, Place RF, Morgan SJ, Gershengorn MC.

Front Endocrinol (Lausanne). 2016 Jul 27;7:105. doi: 10.3389/fendo.2016.00105. eCollection 2016.

18.

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse.

Dougherty JP, Springer DA, Gershengorn MC.

J Vis Exp. 2016 May 31;(111). doi: 10.3791/54052.

19.

TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.

Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC.

J Clin Endocrinol Metab. 2016 Jun;101(6):2340-7. doi: 10.1210/jc.2016-1315. Epub 2016 Apr 4.

20.

Multiple Transduction Pathways Mediate Thyrotropin Receptor Signaling in Preosteoblast-Like Cells.

Boutin A, Neumann S, Gershengorn MC.

Endocrinology. 2016 May;157(5):2173-81. doi: 10.1210/en.2015-2040. Epub 2016 Mar 7.

21.

Future Prospects for the Treatment of Graves' Hyperthyroidism and Eye Disease.

Neumann S, Place RF, Krieger CC, Gershengorn MC.

Horm Metab Res. 2015 Sep;47(10):789-96. doi: 10.1055/s-0035-1555901. Epub 2015 Jul 21. Review.

PMID:
26197854
22.

Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC.

J Clin Endocrinol Metab. 2015 Mar;100(3):1071-7. doi: 10.1210/jc.2014-3566. Epub 2014 Dec 8.

23.

Heritability of fat accumulation in white adipocytes.

Katz LS, Geras-Raaka E, Gershengorn MC.

Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E335-44. doi: 10.1152/ajpendo.00075.2014. Epub 2014 Jun 17.

24.

β-Arrestin-1 mediates thyrotropin-enhanced osteoblast differentiation.

Boutin A, Eliseeva E, Gershengorn MC, Neumann S.

FASEB J. 2014 Aug;28(8):3446-55. doi: 10.1096/fj.14-251124. Epub 2014 Apr 10.

25.

PAR-3 knockdown enhances adhesion rate of PANC-1 cells via increased expression of integrinαv and E-cadherin.

Segal L, Katz LS, Shapira H, Sandbank J, Geras-Raaka E, Gershengorn MC, Oron Y.

PLoS One. 2014 Apr 3;9(4):e93879. doi: 10.1371/journal.pone.0093879. eCollection 2014.

26.

A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.

Krieger CC, Gershengorn MC.

Endocrinology. 2014 Feb;155(2):627-34. doi: 10.1210/en.2013-1890. Epub 2013 Dec 3.

27.

A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice.

Neumann S, Nir EA, Eliseeva E, Huang W, Marugan J, Xiao J, Dulcey AE, Gershengorn MC.

Endocrinology. 2014 Jan;155(1):310-4. doi: 10.1210/en.2013-1835. Epub 2013 Dec 4.

28.

Platelet-derived growth factor BB mimics serum-induced dispersal of pancreatic epithelial cell clusters.

Hiram-Bab S, Katz LS, Shapira H, Sandbank J, Gershengorn MC, Oron Y.

J Cell Physiol. 2014 Jun;229(6):743-51. doi: 10.1002/jcp.24493.

29.

Proteinase-activated receptors differentially modulate in vitro invasion of human pancreatic adenocarcinoma PANC-1 cells in correlation with changes in the expression of CDC42 protein.

Segal L, Katz LS, Lupu-Meiri M, Shapira H, Sandbank J, Gershengorn MC, Oron Y.

Pancreas. 2014 Jan;43(1):103-8. doi: 10.1097/MPA.0b013e31829f0b81.

30.

Persistent cAMP signaling by TSH receptors revealed by phosphodiesterase inhibition.

Geras-Raaka E, Neumann S, Gershengorn MC.

Thyroid. 2013 Nov;23(11):1484-9. doi: 10.1089/thy.2013.0089. Epub 2013 Sep 20.

31.

Reprogramming adult human dermal fibroblasts to islet-like cells by epigenetic modification coupled to transcription factor modulation.

Katz LS, Geras-Raaka E, Gershengorn MC.

Stem Cells Dev. 2013 Sep 15;22(18):2551-60. doi: 10.1089/scd.2013.0134. Epub 2013 Jun 4.

32.

A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS.

J Clin Endocrinol Metab. 2013 May;98(5):2153-9. doi: 10.1210/jc.2013-1149. Epub 2013 Mar 12.

33.

Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice.

Thirunarayanan N, Nir EA, Raaka BM, Gershengorn MC.

Neuropsychopharmacology. 2013 May;38(6):950-6. doi: 10.1038/npp.2012.256. Epub 2012 Dec 11.

34.

Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor.

Thirunarayanan N, Raaka BM, Gershengorn MC.

Front Endocrinol (Lausanne). 2012 Oct 9;3:120. doi: 10.3389/fendo.2012.00120. eCollection 2012.

35.

Update in TSH receptor agonists and antagonists.

Gershengorn MC, Neumann S.

J Clin Endocrinol Metab. 2012 Dec;97(12):4287-92. doi: 10.1210/jc.2012-3080. Epub 2012 Sep 27. Review.

36.

A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.

Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS, Gershengorn MC.

Thyroid. 2012 Aug;22(8):839-43. doi: 10.1089/thy.2011.0520. Epub 2012 Jul 11.

37.

Persistent signaling by thyrotropin-releasing hormone receptors correlates with G-protein and receptor levels.

Boutin A, Allen MD, Neumann S, Gershengorn MC.

FASEB J. 2012 Aug;26(8):3473-82. doi: 10.1096/fj.12-207860. Epub 2012 May 16.

38.

The Synthesis and Evaluation of Dihydroquinazolin-4-ones and Quinazolin-4-ones as Thyroid Stimulating Hormone Receptor Agonists.

Englund EE, Neumann S, Eliseeva E, McCoy JG, Titus S, Zheng W, Southall N, Shin P, Leister W, Thomas CJ, Inglese J, Austin CP, Gershengorn MC, Huang W.

Medchemcomm. 2011 Oct;2(10):1016-1020.

39.

Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.

Lupu-Meiri M, Geras-Raaka E, Lupu R, Shapira H, Sandbank J, Segal L, Gershengorn MC, Oron Y.

J Cell Physiol. 2012 Nov;227(11):3621-8. doi: 10.1002/jcp.24068.

40.

History of the clinical endocrinology branch of the National Institute of Diabetes and Digestive and Kidney Diseases: impact on understanding and treatment of diseases of the thyroid gland.

Gershengorn MC.

Thyroid. 2012 Feb;22(2):109-11. doi: 10.1089/thy.2012.2202.com. Epub 2012 Jan 18. No abstract available. Erratum in: Thyroid. 2012 Apr;22(4):450.

41.

Serum deprivation induces glucose response and intercellular coupling in human pancreatic adenocarcinoma PANC-1 cells.

Hiram-Bab S, Shapira Y, Gershengorn MC, Oron Y.

Pancreas. 2012 Mar;41(2):238-44. doi: 10.1097/MPA.0b013e3182277e56.

42.
43.

Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling.

Allen MD, Neumann S, Gershengorn MC.

FASEB J. 2011 Oct;25(10):3687-94. doi: 10.1096/fj.11-188961. Epub 2011 Jun 24.

44.

Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling.

Boutin A, Allen MD, Geras-Raaka E, Huang W, Neumann S, Gershengorn MC.

Mol Pharmacol. 2011 Aug;80(2):240-6. doi: 10.1124/mol.111.072157. Epub 2011 Apr 27.

45.

Small molecule TSHR agonists and antagonists.

Neumann S, Gershengorn MC.

Ann Endocrinol (Paris). 2011 Apr;72(2):74-6. doi: 10.1016/j.ando.2011.03.002. Epub 2011 Apr 20.

46.

Synthesis, receptor binding, and CNS pharmacological studies of new thyrotropin-releasing hormone (TRH) analogues.

Monga V, Meena CL, Rajput S, Pawar C, Sharma SS, Lu X, Gershengorn MC, Jain R.

ChemMedChem. 2011 Mar 7;6(3):531-43. doi: 10.1002/cmdc.201000481. Epub 2011 Feb 7.

47.

A novel HMM-based method for detecting enriched transcription factor binding sites reveals RUNX3 as a potential target in pancreatic cancer biology.

Levkovitz L, Yosef N, Gershengorn MC, Ruppin E, Sharan R, Oron Y.

PLoS One. 2010 Dec 22;5(12):e14423. doi: 10.1371/journal.pone.0014423.

48.

A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor.

Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengorn MC.

J Clin Endocrinol Metab. 2011 Feb;96(2):548-54. doi: 10.1210/jc.2010-1935. Epub 2010 Dec 1.

49.

Constitutively active thyrotropin and thyrotropin-releasing hormone receptors and their inverse agonists.

Neumann S, Raaka BM, Gershengorn MC.

Methods Enzymol. 2010;485:147-60. doi: 10.1016/B978-0-12-381296-4.00009-9.

50.

Mutations that silence constitutive signaling activity in the allosteric ligand-binding site of the thyrotropin receptor.

Haas AK, Kleinau G, Hoyer I, Neumann S, Furkert J, Rutz C, Schülein R, Gershengorn MC, Krause G.

Cell Mol Life Sci. 2011 Jan;68(1):159-67. doi: 10.1007/s00018-010-0451-2. Epub 2010 Jul 22.

Supplemental Content

Loading ...
Support Center